Abingdon's Latest Contracts Show Huge Diagnostic Test Breakthroughs
Why It Matters
The contracts confirm market demand for Abingdon’s multiplex lateral‑flow platform, unlocking significant revenue and advancing point‑of‑care diagnostic capabilities for biotech and pharma clients.
Key Takeaways
- •Secured $2.5M US contract for clinical diagnostic test management.
- •Won £4.8M deal to develop multiplex lateral flow assays.
- •Multiplex lateral flow enables simultaneous biomarker detection in one device.
- •Offering quantifiable, on‑site lab‑grade tests for biotech and pharma.
- •Full‑service model resonates, driving new revenue streams for Abingdon.
Summary
Abingdon announced two major contracts—a $2.5 million U.S. agreement to manage an international clinical diagnostic program and a £4.8 million UK deal to develop multiplex lateral‑flow tests—underscoring its shift toward a full‑service diagnostic offering.
The first contract funds Abingdon’s oversight of a clinical test development project, while the second funds the creation, regulatory approval, and manufacturing of multiplex lateral‑flow devices that can detect multiple biomarkers on a single strip and deliver quantitative results.
Company executives emphasized that lateral‑flow technology is no longer limited to simple yes/no outcomes; the multiplex format provides on‑site, lab‑grade data that biotech and pharmaceutical customers find “extremely interesting,” especially for rapid, decentralized testing.
These agreements validate Abingdon’s strategy, open sizable new revenue streams, and position the firm at the forefront of point‑of‑care diagnostics, potentially accelerating adoption of advanced multiplex testing across the industry.
Comments
Want to join the conversation?
Loading comments...